Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of KH617 with temozolomide versus investigator's choice therapy or KH617 monotherapy in recurrent glioblastoma
CTR20253070Phase 2Active
- Sponsor
- Honghe Biotech
- Start
- Sep 2025
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of KH617 in glioblastoma (GBM), sponsored by Honghe Biotech. Started Sep 2025; status: active.
02
Drugs
KH617
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20253070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253070.